Brookline Capital Markets Starts (BIOX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts BIOX Hot Sheet
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 10
Join SI Premium – FREE
Brookline Capital Markets analyst Sally Yanchus initiates coverage on (NYSE: BIOX) with a Buy rating and a price target of $13.00.
Analyst says: " The launch of EcoSoy in the US and China could transform BIOX, potentially more than doubling the current annual revenue base of $180m by 2023. The global market for agricultural biological crop offerings including seeds is estimated to be $56B and growing."
For an analyst ratings summary and ratings history on click here. For more ratings news on click here.
Shares of closed at $4.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Glencore Plc (GLC:AU) (GLCNF) at Buy
- Raymond James Starts Atlas Salt Inc (SALT:CN) at Outperform
- Piper Sandler Starts York Space Systems (YSS) at Neutral
Create E-mail Alert Related Categories
Analyst Comments, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
